Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-09-09
Target enrollment:
Participant gender:
Summary
This study will be used to determine the safety and tolerability of BMS-986016 administered
alone and in combination with Nivolumab in subjects with advanced solid tumors.